Literature DB >> 20345899

Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model.

Marc Seidler1, Stefanie Salvenmoser, Frank-Michael C Müller.   

Abstract

The aim of this study was to test whether a Candida albicans biofilm can be eradicated by liposomal amphotericin B (LAMB) at the minimal inhibitory concentration in a novel catheter continuous flow model. After 24-h biofilm formation and a 24-h treatment with LAMB, the growth of the hyphal network was reduced to 20% in comparison with the untreated control, whereas fluconazole and caspofungin remained at an intermediate phase (50%). After 24-h biofilm formation and a 24-h treatment with LAMB, 20% of the surface was covered in biofilm and LAMB caused an uneven surface. For caspofungin and fluconazole, the surface covering was 80%. The extracellular matrix (ECM) of the infected, but untreated catheters had a thickness of 5-20 microm at 24 h and 10-150 microm at 48 h. After 24-h biofilm formation and a 24-h treatment with LAMB, the ECM was virtually cleared with 0 microm ECM. After 24-h biofilm formation and a 24-h treatment with fluconazole, the ECM thickness was comparable to the infected, but untreated catheter at 24 h with 10-25 microm; with caspofungin, the ECM thickness was comparable to the infected, but untreated catheter at 48 h with 10-130 microm. Comparing the blastospores, pseudohyphae and ECM, 0.5 microg mL(-1) LAMB could eradicate Candida biofilm, whereas fluconazole and caspofungin were less effective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345899     DOI: 10.1111/j.1567-1364.2010.00618.x

Source DB:  PubMed          Journal:  FEMS Yeast Res        ISSN: 1567-1356            Impact factor:   2.796


  9 in total

1.  In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.

Authors:  Barbara Fiori; Brunella Posteraro; Riccardo Torelli; Mario Tumbarello; David S Perlin; Giovanni Fadda; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

2.  Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms.

Authors:  Gordon Ramage; Anto Jose; Leighann Sherry; David F Lappin; Brian Jones; Craig Williams
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

3.  Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.

Authors:  Laura Judith Marcos-Zambrano; Marta Gómez-Perosanz; Pilar Escribano; Oscar Zaragoza; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

4.  In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods.

Authors:  Francesca Bugli; Brunella Posteraro; Massimiliano Papi; Riccardo Torelli; Alessandro Maiorana; Francesco Paroni Sterbini; Patrizia Posteraro; Maurizio Sanguinetti; Marco De Spirito
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

5.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Authors:  Frederic Tissot; Samir Agrawal; Livio Pagano; Georgios Petrikkos; Andreas H Groll; Anna Skiada; Cornelia Lass-Flörl; Thierry Calandra; Claudio Viscoli; Raoul Herbrecht
Journal:  Haematologica       Date:  2016-12-23       Impact factor: 9.941

Review 6.  Nanotechnology Fundamentals Applied to Clinical Infectious Diseases and Public Health.

Authors:  Ellis Tobin; Sara Brenner
Journal:  Open Forum Infect Dis       Date:  2021-11-20       Impact factor: 3.835

7.  Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms.

Authors:  Anne-Sophie Messiaen; Katrien Forier; Hans Nelis; Kevin Braeckmans; Tom Coenye
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

Review 8.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08

Review 9.  Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.

Authors:  Sofia Costa-de-Oliveira; Acácio G Rodrigues
Journal:  Microorganisms       Date:  2020-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.